IP Library › Granted Patent US 10,391,127
Granted Patent B2
US 10,391,127 · App. 14/138,577 · Granted Aug 27, 2019

Mesenchymal stem cells and uses therefor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,391,127
App. No.
14/138,577
Granted
Aug 27, 2019
Kind
B2
Abstract

Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Claims (17)

1. A method of limiting inflammation in the gut in a patient suffering from inflammatory bowel disease, the method comprising the step of intravenously or intraarterially administering to the patient a suspension of isolated, cultured, genetically unmanipulated mesenchymal stem cells in an amount effective to limit inflammation in the gut.

2. The method of claim 1 , wherein the suspension further comprises an acceptable pharmaceutical carrier.

3. The method of claim 1 , wherein the suspension is administered in an amount of from about 1×10 5 cells/kg to about 1×10 7 cells/kg.

4. The method of claim 1 , wherein the suspension is administered in an amount of from about 1×10 6 cells/kg to about 5×10 6 cells/kg.

5. The method of claim 1 , wherein the cultured, genetically unmanipulated mesenchymal stem cells are isolated from marrow.

6. The method of claim 5 , wherein the marrow is iliac crest marrow.

7. The method of claim 1 , wherein the administration is intravenous.

8. The method of claim 5 , wherein the administration is intravenous.

9. The method of claim 6 , wherein the administration is intravenous.

10. The method of claim 1 , wherein the administration is intraarterial.

11. The method of claim 5 , wherein the administration is intraarterial.

12. The method of claim 6 , wherein the administration is intraarterial.

13. The method of claim 1 , wherein the mesenchymal stem cells increase secretion of interleukin-10.

14. The method of claim 1 , wherein the mesenchymal stem cells increase generation of regulatory T cells.

15. The method of claim 1 , wherein the patient is human and the mesenchymal stem cells are human.

16. The method of claim 7 , wherein the patient is human and the mesenchymal stem cells are human.

17. The method of claim 10 , wherein the patient is human and the mesenchymal stem cells are human.

Assignments (7)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT AT REEL/FRAME NO. 45759/0917 Recorded Jul 30, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 072297/0753 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 10, 2018
From: MESOBLAST INTERNATIONAL SARL
To: NQP SPV II, L.P., AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 046515/0222 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 28, 2018
From: MESOBLAST INTERNATIONAL SARL
To: HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 045759/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2014
From: AGGARWAL, SUDEEPTA; PITTENGER, MARK F.; VARNEY, TIMOTHY R.
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 034001/0950 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2014
From: OSIRIS THERAPEUTICS, INC.
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 034002/0030 →